Discover
llllllllll VS-6766 / Verastem; defactinib (VS-6063) / VerastemVerastem Oncology Signs Definitive Agreement to Sell COPIKTRA (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors (Businesswire) - Aug 10, 2020 - "The Company has also begun preclinical combination studies investigating VS-6766 and defactinib in combination with KRAS-G12C inhibitors and initial data will be presented at the 2nd Annual RAS-Targeted Drug Development Conference. Based on the positive preclinical data presented at the AACR 2020 Virtual Annual Meeting II, Verastem plans to support a Phase 2 investigator-initiated study evaluating the combination of VS-6766 and defactinib in uveal melanoma, which is expected to begin in late 2020....The company is in a position of financial strength with a cash runway expected to fund the clinical and regulatory milestones and development of VS-6766 and defactinib in LGSOC and KRASmt NSCLC until at least 2024."llllllllll XMT-1536 / Mersana, AdimabMersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer (GlobeNewswire) - Aug 11, 2020 - "Mersana Therapeutics, Inc…announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for XMT-1536, for the treatment of patients with platinum-resistant high-grade serous ovarian cancer who have received up to three prior lines of systemic therapy or patients who have received four prior lines of systemic therapy regardless of platinum status."llllllllll DPX-Survivac (EMD 640744) / IMV IncIMV Inc. Announces Second Quarter 2020 Financial Results (Businesswire) - Aug 12, 2020 - "DPX-Survivac: Top line Phase 2 clinical results from the DLBCL combination trial in 2020; Top line Phase 2 clinical results from the ovarian monotherapy trial in 2020; Updated Phase 2 clinical results from the basket trial in 2020."llllllllll ofranergene obadenovec (VB-111) / NanoCarrier, VBL TherapeuticsVBL Therapeutics Announces Second Successful Pre-planned Interim Analysis with a Positive Data Safety Monitoring Committee Review Looking at OS - the Primary Endpoint of the OVAL Phase 3 Potential Registration Study of VB-111 in Ovarian Cancer (GlobeNewswire) - Aug 12, 2020 - P3, N=400; OVAL (NCT03398655); Sponsor: VBL Therapeutics; "VBL Therapeutics…announced today that the independent Data Safety Monitoring Committee (DSMC) has completed its second, pre-planned interim analysis in the ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111) in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned. In this second interim analysis, the DSMC reviewed unblinded Overall Survival (OS) data of the first 100 randomized patients with a followup of at least 3 months. OS is the primary endpoint of the OVAL study. The committee also looked at response rate and safety information…The next DSMC review in the OVAL study is expected in the first quarter of 2021."llllllllll defactinib (VS-6063) / Verastem; VS-6766 / VerastemVerastem Oncology Signs Definitive Agreement to Sell COPIKTRA (duvelisib) Rights to Secura Bio to Focus on Development of VS-6766 and Defactinib in KRAS Mutant Solid Tumors (Businesswire) - Aug 10, 2020 - "Verastem announced...that the company met with the FDA in July 2020 to discuss the registration-directed study design for the VS-6766/defactinib combination in patients with LGSOC...Verastem’s NSCLC study will also be an adaptive design with a focus on patients with KRAS-G12V mutant tumors...Verastem expects to commence registration-directed clinical trials for potential accelerated approval in LGSOC and KRASmt NSCLC by the end of 2020...The FRAME study is now expanding to include new cohorts in pancreatic cancer, KRASmt endometrial cancer and KRAS-G12V NSCLC... additional data from the NSCLC cohort of the FRAME study will be submitted to the International Association for the Study of Lung Cancer (IASLC) World Lung Cancer Conference, taking place in January 2021."
